Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Nvidia Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Nvidia Corp trades at $219.13 (market cap $5.52T). The key difference: Nvidia Corp is far larger — about 5673.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Nvidia Corp for 116 Days on average.
| MRVI | NVDA | |
|---|---|---|
Market Cap | $972.90M | $5.52T |
Volume | 4,325,710 | 84,036,941 |
Sector | Health | Technology |
52-Week High | $9.00 | $239.27 |
52-Week Low | $2.83 | $165.17 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $1.08B | $5.49T |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NVIDIA (NVDA) trades at $221.51, down 2.13% today, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $221. Fundamentally, the company reported stellar revenue growth to $130.50 billion in 2025 and a net income margin of 63.66%, though valuation ratios like a P/E of 28.89 and P/S of 18.4 remain elevated. Recent news highlights AI-driven growth potential but also concerns over market saturation.
Outlook: Strong AI demand and earnings beats support long-term growth, but high valuations and competitive pressures pose risks. Analyst consensus is bullish with a $339.17 price target, suggesting significant upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
